What is HC Wainwright’s Estimate for BCAX Q1 Earnings?

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Bicara Therapeutics in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($1.11) for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q2 2027 earnings at ($1.14) EPS, Q3 2027 earnings at ($1.17) EPS, Q4 2027 earnings at ($1.21) EPS and FY2027 earnings at ($4.63) EPS.

A number of other research firms have also recently issued reports on BCAX. Citigroup reiterated a “market outperform” rating on shares of Bicara Therapeutics in a report on Tuesday. The Goldman Sachs Group lowered Bicara Therapeutics from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $20.00 to $8.00 in a research report on Friday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, October 2nd. Wells Fargo & Company boosted their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Finally, BMO Capital Markets initiated coverage on Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

Bicara Therapeutics Price Performance

BCAX stock opened at $10.53 on Thursday. The firm has a 50 day simple moving average of $17.37 and a two-hundred day simple moving average of $20.84. The stock has a market cap of $696.80 million, a PE ratio of -3.03 and a beta of -0.33. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.22).

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of the business. Siren L.L.C. raised its holdings in shares of Bicara Therapeutics by 11.2% during the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after purchasing an additional 586,001 shares during the last quarter. BlackRock Inc. purchased a new stake in Bicara Therapeutics in the second quarter worth approximately $114,250,000. Janus Henderson Group PLC boosted its holdings in Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after purchasing an additional 692,933 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Bicara Therapeutics in the second quarter worth approximately $93,957,000. Finally, Orbimed Advisors LLC grew its position in Bicara Therapeutics by 219.1% in the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after purchasing an additional 458,200 shares during the period.

Insider Buying and Selling

In other news, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the sale, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.80% of the company’s stock.

Recent Bicara Therapeutics Headlines

Here are a few of the latest headlines about BCAX:

• Positive Sentiment: HC Wainwright maintained its Buy rating and a $36 price target, indicating continued confidence despite lowering its target from $42. HC Wainwright recommendation
• Negative Sentiment: New headlines report that Stifel Nicolaus and Morgan Stanley cut their BCAX price targets, while BTIG Research issued a pessimistic stock-price forecast. Further target reductions may weigh on sentiment, even though prior reports showed these firms retained positive ratings. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright forecasts a 2027 loss of $4.63 per share, with quarterly losses increasing from $1.11 in Q1 to $1.21 in Q4. That is a larger full-year loss than the cited current-year consensus estimate of $3.58 per share, highlighting continued cash-burning expectations. Bicara Therapeutics analyst coverage

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.